Semaglutide Fails Alzheimer's Trials, Novo Nordisk Shares Drop
Update: 2025-11-24
Description
Semaglutide, Novo Nordisks oral drug, failed to meet its primary goal in Alzheimers trials, causing a ten percent drop in share price. Despite this setback, the company emphasizes the drugs benefits for diabetes, obesity, and related conditions. The trials involved over 3,800 patients, aiming for a twenty percent slowing of cognitive decline over two years.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
